The company recently launched a clinical trial of its CLAAS implant. The implant features foam-based architecture designed to help simplify left atrial appendage occlusion procedures and create a uniform seal.
Sprig Equity led the financing round, according to a June 5 Conformal Medical news release.
“Conformal Medical is committed to bringing the innovative CLAAS System to the large and rapidly growing LAAO market in the United States,” Conformal CEO James Reinstein said in the release. “The series D funding provides us the resources to complete enrollment in the Conform trial, drive iterative development projects, and broaden the clinical experience of the CLAAS system in expanded geographies.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
